News

Clinicians against DTC testing
Enlarge image

PolicyBelgiumFranceEU

Clinicians against DTC testing

27.05.2013 - A survey of European clinical geneticists show that a vast majority reject direct-to-consumer (DTC) genetic testing without prior face-to-face counselling.

According to the survey, carried out by Heidi Carmen Howard from French INSERM and Pascal Borry from KU Leuven among 131 EU geneticists, DCT testing for monogenetic and complex diseases is more widespread than thought before. 44% of patients who asked their doctor for genetic counselling, had previously already undertaken a DCT test (Genome Medicine). However, the respondents seem concerned about the DCT test offers. 84% of them disagreed with replacing face-to-face supervision by a medical doctor with supervision via telephone, which is offered by some DTC testing firms. Over 85% of respondents said that they would offer genetic counselling to patients who asked for a consultation after having undergone DTC genetic testing

A majority of clinical geneticists also found it unacceptable to provide non-face-to-face medical supervision for: a pre-symptomatic test for a condition with very high penetrance; a predictive test for a condition that has a “medium” penetrance of 50 to 60%; and for carrier testing. For conditions that are neither treatable nor preventable and for disorders with serious health consequences, clinical geneticists were almost unanimous in expressing the unacceptability of offering such genetic tests outside of the traditional health care setting, without an established physician-patient relationship and without face-to-face medical supervision.

Recently, the German Ethics Council tabled recommendations on genetic diagnosis to the government asking for international rules for DCT testing and a duty to have face-to-face counselling before any of those tests. According to the survey, patients need qualified information on clinical significance, medical relevance and validity of such tests.

 © eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/eu-geneticists-against-dtc-testing.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF21.8%
  • MAGFORCE6.90 EUR10.8%
  • BB BIOTECH140.45 EUR5.1%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.85 EUR-19.5%
  • VITA 343.75 EUR-17.6%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR188.4%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-68.1%
  • MERCK KGAA66.20 EUR-43.4%

No liability assumed, Date: 26.08.2014